PolyPid Ltd. filings document foreign private issuer disclosures for a biopharmaceutical company developing PLEX-based controlled-release therapeutics. Form 6-K reports furnish corporate updates, financial results, FDA and NDA-related disclosures for D-PLEX100, SHIELD II clinical and pharmacokinetic information, GMP inspection updates, and business-operation summaries.
The company’s regulatory record also covers capital-structure and governance matters, including ordinary-share sales agreement disclosures, legal opinions tied to share issuance, Form F-3 and Form S-8 registration statement references, shareholder meeting results, board composition, director compensation approvals, and risk and operating disclosures incorporated into its SEC registration framework.
PolyPid Ltd. filed a Form S-8 to register 1,200,000 additional ordinary shares for issuance under the Amended and Restated 2012 Share Option Plan, incremental to 2,311,570 shares previously registered. The Registration Statement incorporates by reference the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2024 and specified Form 6-K reports that include recent financial results for the quarters and six-month periods ended June 30, 2025.
The company's amended articles will permit exemption, indemnification and insurance of officers to the fullest extent allowed under Israeli law; PolyPid intends to obtain directors and officers liability insurance and to enter into indemnification and exemption agreements with officers, while noting the SEC view that indemnification against Securities Act liabilities is unenforceable. The filing indicates the company is an emerging growth company and a non-accelerated filer.
Rosalind Advisors, related individuals and a fund report collective beneficial ownership of 5,762,349 common shares of PolyPid Ltd., representing 9.9% of the outstanding common stock based on 15,897,201 shares outstanding per the issuer's disclosure. The reported position consists of 975,462 shares of Common Stock and 4,786,887 shares issuable upon exercise of warrants.
The filings show shared voting and dispositive power over 5,762,349 shares and no sole voting or dispositive power. The warrants include a blocker provision that prevents exercise to the extent it would increase beneficial ownership above 9.99%, and the filing states actual ownership after giving effect to those blockers is less than the amounts reported.
PolyPid Ltd. reports a leadership change and links recent financial disclosures to its U.S. registration statements. The company notes that Jacob Harel’s service as director and chairman ended at the June 25, 2025 shareholder meeting. On August 11, 2025, the board elected existing director Nir Dror as Interim Chairman of the Board, to serve until further notice or another board decision.
The filing also records that on August 13, 2025 PolyPid issued a press release titled “PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results.” Specified sections of that release, including corporate highlights, financial results for the three and six months ended June 30, 2025, balance sheet highlights, forward-looking statements and the attached financial statements, are incorporated by reference into several of PolyPid’s Form F-3 and Form S-8 registration statements.
PolyPid Ltd., an Israel-based biopharmaceutical company, filed a Form 6-K to furnish a press release announcing the appointment of Dr. Nurit Tweezer-Zaks as its Chief Medical Officer. This leadership change relates to oversight of the company’s medical and clinical activities.
The filing also states that the first and third paragraphs of the press release, along with its “Forward-Looking Statements” section, are incorporated by reference into several of PolyPid’s effective registration statements on Forms F-3 and S-8, so that these disclosures become part of those offering documents going forward.
PolyPid held its Annual and Extraordinary General Meeting on June 25, 2025, where shareholders approved all seven proposed resolutions. Key approvals include:
- Re-appointment of Kost Forer Gabbay & Kasierer as independent auditors
- Re-election of eight board members with approved compensation
- New option grants for non-executive directors
- Two separate option grants for CEO Dikla Czaczkes Akselbrad: - Standard option grant - Additional milestone-based option grant
- Renewal of company's compensation policy
- Acceleration of unvested options for departing Board Chairman Jacob Harel
The meeting also included discussion of financial statements for FY2024. The approved changes to compensation and governance structure indicate strategic moves to retain leadership and align management incentives with company performance. The filing was incorporated into multiple Form F-3 and S-8 registration statements.
PolyPid, an Israeli biotechnology company established over five years ago, has filed Form D to report an exempt securities offering under Rule 506(b). The company has successfully completed a $26,692,799 offering, with all securities now sold to 20 investors.
The offering includes equity securities, along with options/warrants and their underlying securities. The company, which currently reports no revenues, maintains its principal operations at 18 Hasivim Street, Petach Tikva, Israel.
Key management includes:
- Four executive officers: Dikla Czaczkes Akselbrad, Dalit Hazan, Ori Warshavsky, and Jonny Missulawin
- Eight independent directors including Jacob Harel, Yechezkel Barenholz, and others
The offering involves no sales commissions or finder's fees, and none of the proceeds are designated for payments to executives or directors. The offering is not connected to any business combination transaction and is not intended to last more than one year.